Development of a Lab-on-a-Chip Biosensor for Clozapine Monitoring

Deanna L. Kelly, Hadar Ben-Yoav, Veronika Stock, Thomas Winkler, Gregory Payne, Sheryl Chocron, Eunkyoung Kim, Gopal Vyas, Raymond Love, Heidi J. Wehring, Kelli M. Sullivan, Stephanie Feldman, Fang Liu, Robert P. McMahon, Reza Ghodssi

Research output: Contribution to journalMeeting Abstract

Abstract

Background: Schizophrenia is a lifelong illness with little recent progress in new pharmacologic treatments. Cloza-pine (CLZ) is the most effective antipsychotic drug for schizophrenia treatment. Yet, it remains underutilized since frequent blood draws are required to monitor white blood cell (WBC) counts. In addition, the evidence-based and recommended use of CLZ blood levels to guide treatment response are often underutilized by clinicians. Real-time monitoring of treatment efficacy and safety will enable personalized medicine and better utilization of CLZ. Labon-a-chip (LOC) biosensing devices are a promising solution and provide numerous advantages, such as small sample volume, ease of use, fast response, low cost, and high throughput. This could allow on-site testing with immediate results at the point-of-care, such as the pharmacy or physicians office. To date it is unknown if this technology would be accepted and utilized by clinicians and if CLZ detection could be done through a LOC.
Original languageEnglish
Article numberM188
Pages (from-to)S237-S238
Number of pages2
JournalNeuropsychopharmacology
Volume38
Issue numberS2
StatePublished - Dec 2013

Keywords

  • Clozapine
  • Biosensor
  • Blood levels
  • Monitoring

Fingerprint

Dive into the research topics of 'Development of a Lab-on-a-Chip Biosensor for Clozapine Monitoring'. Together they form a unique fingerprint.

Cite this